GE HealthCare Unveils Logiq Totus Ultrasound at ECR
Designed for full-body imaging, the new modality reportedly offers a lightweight portable design, AI-powered tools and enhanced high-resolution images.
Emphasizing a combination of workflow enhancements and advances to facilitate improved image quality, GE HealthCare has launched the Logiq Totus ultrasound system at the European Congress of Radiology.
Use of the Logiq Totus ultrasound system enables access to a wide range of transducers to help foster high resolution for a variety of areas, advanced tools such as 2D Shear Wave Elastography and access to cSound™ Architecture, which provides enhanced consistent image quality, according to GE HealthCare.
GE HealthCare said the Logiq Totus ultrasound system, launched at the European Congress of Radiology, offers a combination of workflow enhancements and advances to facilitate improved image quality. (Image courtesy of GE HealthCare.)
The company said other advantages with the lightweight, portable system include tools such as Scan Assistant and Voice Control that help streamline workflows, and access to Breast and Thyroid Assistant artificial intelligence (AI) support tools from Koios Medical.
“ … We’re focused on driving innovation that enables precision care, and the enhanced (Logiq) portfolio allows us to deliver on this promise with products and solutions that help clinicians optimize care with ease and efficiency,” said Jyoti Gera, the general manager of General Imaging and Primary Care, Ultrasound at GE HealthCare.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
